BBS7 divergent transcript (BBS7-DT)

There is no credible evidence in published scientific literature or biomedical databases that "BBS7 divergent transcript" (BBS7-DT) is a protein, enzyme, receptor, or any other canonical drug target class. "Divergent transcript" refers generally to a long noncoding RNA transcript expressed from the opposite DNA strand near the BBS7 gene locus. The main research on Bardet-Biedl syndrome (BBS) involves the protein-coding gene BBS7, which is implicated in ciliopathy and intracellular protein trafficking, not the divergent transcript[1][2][3][4]. No molecular or disease role, druggability, or biomarker status is established for BBS7-DT. If your interest is in the protein-coding BBS7 gene (Bardet-Biedl syndrome 7 protein), that is a different entity with established biological roles in cilia function and disease, although not directly as a druggable receptor or enzyme[1][3][4]. If this was your intent, clarification is advised.

Other names

BBS7-DT